Provider review · Updated September 29, 2026
Myla Health hot-flash review: bring both the daytime and overnight account
Myla’s UK consultation model includes symptom discussion and follow-up, with separate medicine costs and defined ongoing-prescribing requirements.
Public-source editorial research · No clinician sign-off or firsthand treatment testing
Myla Health offers UK private appointments for menopause and hormonal-health concerns, with face-to-face and video options. Its published consultation description includes discussing symptoms and their effect on life. That is a relevant starting point for someone whose daytime heat episodes and nighttime sleeping difficulties do not tell exactly the same story.
We reviewed Myla's service, FAQ and price records on September 29, 2026. This review asks how the first conversation, written plan and later review are organized, while retaining the differences between private prescribing, NHS decisions and medicine charges. It does not verify a booking, a chosen nonhormonal product, a diagnosis of insomnia or an individual response to care.
A private appointment can establish a care discussion. It does not guarantee an NHS prescription, a specific nonhormonal medicine or a sleep outcome.
In this article
1. The first visit concerns symptoms and their impact
Myla's service description says the initial consultation lasts approximately 45 minutes and includes symptoms, concerns and their effect on life. Treatment is discussed after that assessment. The record does not establish a fixed prescription that follows automatically from reporting night sweats or disturbed sleep.
The Newson Clinic review considers another UK private pathway with different appointment pricing. A useful comparison concerns the actual visit and responsibility for follow-up, rather than unsupported claims about which clinic produces better sleep. Our frequency, severity and impact guide helps organize the different observations a clinician may need.
2. Nighttime symptoms do not establish a single cause
NIA's menopause sleep guidance explains that hot flashes, mood and other circumstances can contribute to poor sleep. It does not say that every awakening proves a vasomotor episode. For an appointment, it can be useful to describe what was noticed during the night and what the following day was like, without assigning the cause in advance.
Myla's consultation record supports a symptom discussion, not an already verified specialist sleep investigation. The night-sweats and sleep guide keeps the distinction visible. If the concern is persistent insomnia, ask what assessment or referral is available rather than assuming it is included in a menopause appointment.
3. A written recommendation and an NHS prescription differ
Myla's FAQ says the private clinic issues private prescriptions and may send treatment recommendations to the patient's NHS GP. It cannot itself issue an NHS prescription. The FAQ also limits consultations to patients physically in the UK during the appointment and requires a UK address for medication deliveries. The selected GP must make the relevant NHS prescribing decision. Private pharmacy arrangements likewise do not confirm a particular medicine or stock position before assessment.
The Mass General Brigham review describes a US regional clinical pathway, which is a different access model. A US product label discussed on this site is not proof that a UK clinic will prescribe that brand. Geography, medicine regulation and clinical responsibility must remain attached to the actual care arrangement.
4. Keep appointment charges separate from medicine charges
The published Myla prices list £290 for an initial 45-minute appointment and £190 for a 30-minute follow-up. The document also describes a £35 private-prescription administration charge after the initial three-month period. That administration fee is not the price of the medicine dispensed by the pharmacy; medicine charges remain separate.
The FAQ describes payment at booking. A price for the appointment therefore should not be advertised as an all-inclusive hot-flash treatment cost. Before booking, confirm the selected clinician, visit type, any investigation charges and which prescribing route would apply if treatment is agreed.
5. The cancellation wording uses two different time measures
Myla's FAQ publishes a 100% cancellation charge for less than 24 hours' notice and a 50% charge for more than 24 hours but fewer than two working days. Another line says that more than 48 hours' notice carries no fee. Working days and clock hours are not necessarily equivalent, so this review does not silently reconcile them into one rule.
The selected booking terms should clarify the applicable cutoff. That is especially relevant when planning travel or arranging help for an in-person appointment. These are the clinic's commercial conditions, not medical guidance about how long a symptom should be observed before seeking care.
6. Continued prescribing has an explicit review requirement
The FAQ requires an annual 30-minute review when Myla continues prescribing. After more than 18 months since the last visit, it asks for a new 45-minute appointment. Those are clinic access and prescribing conditions, not this site's recommended treatment interval. Myla also distinguishes brief email clarifications from more complex issues that need an appointment.
At review, daytime symptom burden and sleep experience can be discussed separately. The claim checklist helps identify what a provider has actually promised to evaluate. A renewal fee or an annual appointment label cannot, by itself, demonstrate that a particular symptom has improved or that a treatment remains suitable.
7. Ask what happens when one goal improves and another does not
Myla documents a follow-up process, but the reviewed pages do not prove an exact Veozah, Lynkuet or Brisdelle offer, nor a guaranteed night-sweat or insomnia outcome. A clinical conversation should be able to revisit a continuing sleep concern even if daytime heat episodes have eased. That is a question about the individual's experience, not a demand to reproduce a trial average.
The nonhormonal risk guide also keeps unwanted effects and other medicines in view. NIA's guidance supports discussing persistent sleep difficulties with a professional. The verified Myla record concerns a qualified UK consultation and follow-up pathway, with the actual treatment still dependent on assessment.
Source notes
References support the claims beside them. Provider pages describe an offer; they do not demonstrate treatment outcomes.
- Myla Health: consultation servicesUK private clinical service; NHS prescribing remains separate · Checked 2026-09-29
- NIA: sleep problems and menopausePatient guidance, content reviewed September 30, 2021; multiple contributors and distinct insomnia assessment · Checked 2026-09-29
- Myla Health: patient FAQsUK location, billing, cancellation and investigation responsibility conditions · Checked 2026-09-29
- Myla Health: prices effective April 1, 2026UK visit and prescription-administration fees, excluding actual medicine · Checked 2026-09-29